

**Amendments to the Specification:**

Please replace the paragraph at page 8, beginning at line 20, and ending at page 9, line 5 with the following amended paragraph:

The compounds can also be used in combination with other agents for treating glaucoma, such as, but not limited to,  $\beta$ -blockers (e.g., timolol, betaxolol, levobetaxolol, carteolol, levobunolol, propranolol), carbonic anhydrase inhibitors (e.g., brinzolamide and dorzolamide),  $\alpha_1$  antagonists (e.g., nipradolol),  $\alpha_2$  agonists (e.g. iopidine and brimonidine), miotics (e.g., pilocarpine and epinephrine), prostaglandin analogs (e.g., latanoprost, travaprost, unoprostone, and compounds set forth in U.S. Patent Nos. 5,889,052; 5,296,504; 5,422,368; and 5,151,444, "hypotensive lipids" (e.g., bimatoprost and compounds set forth in 5,352,708), and neuroprotectants (e.g., compounds from U.S. Patent No. 4,690,931, particularly eliprodil and R-eliprodil, as set forth in a pending application U.S.S.N. ~~06/203,350~~ 60/203,350, and appropriate compounds from WO 94/13275, including memantine.

Please replace the paragraph at page 10, beginning at line 2, and ending at line 5 with the following amended paragraph:

A method to ~~block~~ activate or bind to serotonin receptors comprising administering an effective amount of at least one compound of Formula 1 to a patient is a further embodiment of the present application. The dosage amounts and other optional components can be used in this embodiment as well.